Tech Company Financing Transactions

Bolt Biotherapeutics Funding Round

Bolt Biotherapeutics closed a $54 million Series B funding round on 2/6/2019. Investors included Pivotal bioVenture Partners, Nan Fung Life Sciences and Novo Ventures.

Transaction Overview

Company Name
Bolt Biotherapeutics
Announced On
2/6/2019
Transaction Type
Venture Equity
Amount
$54,000,000
Round
Series B
Investors

Pivotal bioVenture Partners (Lead Investor) (Ash Khanna)

Nan Fung Life Sciences

Novo Ventures (Peter Moldt)

Vivo Capital

Proceeds Purpose
The funds will be used to advance the company's lead Boltbody Immune-Stimulating Antibody Conjugate (ISAC) into the clinic as well as to build the company's pipeline and further develop its technology platform.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
640 Galveston Dr.
Redwood City, CA 94063
USA
Phone
(650) 665-9295
Website
www.boltbio.com
Email Address
[email protected]
Overview
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a private biotechnology company developing Boltbody Immune-stimulating Antibody Conjugates (ISAC), a new class of cancer therapeutics. These systemically-administered, tumor-targeted Boltbody therapeutics unleash the immune system to induce anti-tumor immunity.
Profile
Bolt Biotherapeutics LinkedIn Company Profile
Social Media
Bolt Biotherapeutics Company Twitter Account
Company News
Bolt Biotherapeutics News
Facebook
Bolt Biotherapeutics on Facebook
YouTube
Bolt Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Peter Moldt
  Peter Moldt LinkedIn Profile  Peter Moldt Twitter Account  Peter Moldt News  Peter Moldt on Facebook
Chief Executive Officer
Randall Schatzman
  Randall Schatzman LinkedIn Profile  Randall Schatzman Twitter Account  Randall Schatzman News  Randall Schatzman on Facebook
Chief Financial Officer
William Quinn
  William Quinn LinkedIn Profile  William Quinn Twitter Account  William Quinn News  William Quinn on Facebook
Chief Medical Officer
Edith Perez
  Edith Perez LinkedIn Profile  Edith Perez Twitter Account  Edith Perez News  Edith Perez on Facebook
Vice President
Michael Alonso
  Michael Alonso LinkedIn Profile  Michael Alonso Twitter Account  Michael Alonso News  Michael Alonso on Facebook
Vice President
Nathan Ihle
  Nathan Ihle LinkedIn Profile  Nathan Ihle Twitter Account  Nathan Ihle News  Nathan Ihle on Facebook
Vice President
Marcin Kowanetz
  Marcin Kowanetz LinkedIn Profile  Marcin Kowanetz Twitter Account  Marcin Kowanetz News  Marcin Kowanetz on Facebook
Vice President
Brian Safina
  Brian Safina LinkedIn Profile  Brian Safina Twitter Account  Brian Safina News  Brian Safina on Facebook
VP - Bus. Development
Grant Yonehiro
  Grant Yonehiro LinkedIn Profile  Grant Yonehiro Twitter Account  Grant Yonehiro News  Grant Yonehiro on Facebook
VP - Engineering
Karla Henning
  Karla Henning LinkedIn Profile  Karla Henning Twitter Account  Karla Henning News  Karla Henning on Facebook
VP - Manufacturing
Travis Tani
  Travis Tani LinkedIn Profile  Travis Tani Twitter Account  Travis Tani News  Travis Tani on Facebook
VP - R & D
David Dornan
  David Dornan LinkedIn Profile  David Dornan Twitter Account  David Dornan News  David Dornan on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/6/2019: By Humankind venture capital transaction
Next: 2/6/2019: Transient Plasma Systems venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2025. Gaebler Ventures. All rights reserved.